Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07213804CT.gov A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sofetabart Mipitecan (this asset) | Eli Lilly and Company | P3 | B · 60 |
| Carboplatin | Eli Lilly and Company | P3 | BBB |
| Adriamycin | Eli Lilly and Company | P3 | BBB |
| Fluorouracilum | AstraZeneca | P2 | BB |
| Patupilone | Novartis Pharmaceuticals | P3 | BB |
| Nogitecan | Eli Lilly and Company | P3 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | B |
| Nintedanib | Boehringer Ingelheim | P3 | B |
+36 more in the Peritoneal Neoplasm cohort
Other indications for Sofetabart Mipitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Neoplasm | — | P3 | B · 60 |
| Ovarian Neoplasm | — | P3 | CCC · 54 |
| Metastatic Neoplasm | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sofetabart Mipitecan in Peritoneal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sofetabart-mipitecan-peritoneal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →